Life Technologies has begun clinical trials to prove the safety and effectiveness of sequence-based typing on its 3500 Dx Genetic Analyzer for analyzing the Human Leukocyte Antigen region and plans to apply for 510(k) clearance of the SBT platform, the company said this week.

An undisclosed clinical research organization will oversee the clinical trials at several independent, accredited HLA typing laboratories in the US. These labs will use the 3500 Dx Genetic Analyzer, SeCore kits, and uType Dx software to analyze six gene regions of the HLA system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.